AngenMed Therapeutics INC.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
ANG-NeoSync® Innovative Immune Cell Therapy Platform. DC/T cell products, comprehensively targeting tumor neoantigens. Patented tumor neoantigen mRNA, enabling personalized and precise targeting for immune cell therapy. Specific tumor therapy, delivering superior efficacy and safety.
Product Development:
1. AGT-NeoAgs panel: First, whole-genome sequencing is performed to obtain mutation information from the tumor, identifying potential neoantigen targets. Based on these customized targets, neoantigen mRNA vaccines are synthesized to be used for the subsequent training of cell products. Concurrently, the patient's immune cells are collected, and dendritic cells (DCs) and T cells are isolated for the preparation of NeoPrime® DC and NeoBoost® T-cells.
2. AGT-NeoPrime® DC: NeoPrime® DC is the tumor neoantigen-specific DC produced by AngenMed Therapeutics INC. DCs act as the "teachers" of T cells. After being isolated from the patient's immune cells, they are introduced to the neoantigen mRNA vaccine for DC differentiation training and cultivation. Through antigen presentation, the DCs express these "teaching materials" to subsequently train T cells to recognize cancer targets.
3. AGT-NeoBoost® T-cells: T cells isolated from white blood cells are co-cultured with NeoPrime® DC to expand tumor neoantigen-specific T cells, yielding the final NeoBoost® T-cells product. Having been trained by the neoantigen-specific DCs, these T cells acquire tumor-recognition capabilities and can be expanded by more than 100-fold. Acting like a massive arsenal of specific anti-cancer weapons assembled in vitro, they precisely eradicate tumor cells.
Product Development:
1. AGT-NeoAgs panel: First, whole-genome sequencing is performed to obtain mutation information from the tumor, identifying potential neoantigen targets. Based on these customized targets, neoantigen mRNA vaccines are synthesized to be used for the subsequent training of cell products. Concurrently, the patient's immune cells are collected, and dendritic cells (DCs) and T cells are isolated for the preparation of NeoPrime® DC and NeoBoost® T-cells.
2. AGT-NeoPrime® DC: NeoPrime® DC is the tumor neoantigen-specific DC produced by AngenMed Therapeutics INC. DCs act as the "teachers" of T cells. After being isolated from the patient's immune cells, they are introduced to the neoantigen mRNA vaccine for DC differentiation training and cultivation. Through antigen presentation, the DCs express these "teaching materials" to subsequently train T cells to recognize cancer targets.
3. AGT-NeoBoost® T-cells: T cells isolated from white blood cells are co-cultured with NeoPrime® DC to expand tumor neoantigen-specific T cells, yielding the final NeoBoost® T-cells product. Having been trained by the neoantigen-specific DCs, these T cells acquire tumor-recognition capabilities and can be expanded by more than 100-fold. Acting like a massive arsenal of specific anti-cancer weapons assembled in vitro, they precisely eradicate tumor cells.
The content above was translated by Ai
Founded Year
2024
Unified Business No.
95461381
Status
Active
Number of Employees
25
Total Paid-in
Capital
172,332,670 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
AngenMed Therapeutics INC. is a clinical-stage biotechnology company focusing on the design and development of precision immune cell therapies to eliminate and prevent the occurrence of cancer. We are committed to bridging the gap between cutting-edge research and clinical application. By providing breakthrough innovative technologies, we realize the goal of curing cancer patients.
The content above was translated by Ai
